Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma
Liu Song1, Zhang Fan2, Niu Jun3
1Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Abstract:
Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.
Insights
Targeted delivery of Integrinβ6 small interfering RNA (siRNA) using immunoliposomes shows promise for colon cancer therapy. This approach effectively suppresses tumor growth, invasion, and metastasis by targeting specific cancer cells.
Area of Science:
- Oncology
- Gene Therapy
- Nanomedicine
Background:
- Adjuvant chemotherapy shows limited efficacy in colon cancer due to insufficient therapeutic response.
- Gene therapy with small interfering RNAs (siRNAs) offers a targeted approach for tumor treatment.
- Integrinβ6 is overexpressed in malignant colonic epithelia, correlating with colon cancer progression, metastasis, and chemoresistance.
Purpose of the Study:
- To design an efficient and targeted delivery system for Integrinβ6-specific siRNA to enhance colon cancer therapy.
- To evaluate the efficacy of Integrinβ6-targeted immunoliposomes for delivering β6-siRNA in colon cancer treatment.
Main Methods:
- Development of Integrinβ6-targeted immunoliposomes for selective delivery of β6-siRNA.
- Assessment of the delivery system's efficiency in colon cancer cells.
- Evaluation of the therapeutic effects on colon cancer cell growth, invasion, and metastasis in vitro.
- In vivo studies to assess tumor growth inhibition.
Main Results:
- The designed Integrinβ6-targeted immunoliposomes achieved highly efficient and selective delivery of β6-siRNA in colon cancer.
- Significant suppression of colon cancer cell growth, invasion, and metastasis was observed.
- The treatment demonstrated substantial inhibition of tumor growth in vivo.
Conclusions:
- Integrinβ6-targeted immunoliposomes represent a potent strategy for delivering β6-siRNA in colon cancer.
- This targeted gene therapy approach holds potential for improving therapeutic outcomes in colon cancer by inhibiting tumor progression and metastasis.
